MedTrace Logo

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

NCT03935984 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-09-19

No results posted yet for this study

Summary

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Conditions

  • Primary Hyperparathyroidism
  • Hypercalcemia

Interventions

DRUG

Calcitonin

Treatment with calcitonin to lower high calcium levels prior to reimaging exam

Sponsors & Collaborators

  • University of Toledo Health Science Campus

    collaborator OTHER

  • Joseph Sferra

    lead OTHER

Principal Investigators

  • Joseph Sferra, MD · University of Toledo College of Medicine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2026-06-01
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03935984 on ClinicalTrials.gov